Spasticity

Neurology India

Volumn 50, Issue 3, 2002, Pages 235-237

  Behari, M ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ACETYLCHOLINE; ALCOHOL; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BACLOFEN; BOTULINUM TOXIN; CLONIDINE; DANTROLENE; DIAZEPAM; GABAERGIC RECEPTOR AFFECTING AGENT; GABAPENTIN; HYDANTOIN DERIVATIVE; IMIDAZOLE DERIVATIVE; PHENOL; TIZANIDINE;

ACETYLCHOLINE RELEASE; BRADYCARDIA; COGNITIVE DEFECT; CONSTIPATION; DECEREBRATION; DEPRESSION; DIARRHEA; DISABILITY; DORSAL RHIZOTOMY; DROWSINESS; DRUG COST; DRUG INHIBITION; EDITORIAL; FATIGUE; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTENSION; LIVER FUNCTION; LIVER TOXICITY; MUSCLE RIGIDITY; MUSCLE TONE; MUSCLE WEAKNESS; MYOTATIC REFLEX; NAUSEA; NERVE BLOCK; PHYSIOTHERAPY; PREMOTOR CORTEX; PYRAMIDAL TRACT; SEDATION; SIDE EFFECT; SPASTICITY; SPINAL CORD STIMULATION; TENDON TRANSFER; TENOTOMY; VELOCITY; VERTIGO; XEROSTOMIA;

HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCLE SPASTICITY;

EID: 0036756486     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Sherrington CS: Decerebrate rigidity and reflex coordination of movements. J Physiol (Lond) 1898; 22: 319-332.
2. Sherrington CS: On plastic tonus and propriocep-tives reflexes. Q J Exp Physiol 1909; 2: 109-156.
3. Nathan P: Some comments on spasticity and rigidity. In: New developments in electromyography and clinical neurophysiology. Desmedt JE (ed.). Basel, Karger, 1973; 13-14.
4. Lance JW: Symposium synopsis. In: Spasticity: disordered motor control chicago, Feldman RG, Young RR, Koella WP (eds.). Year Book Medical Publishers. 1980.
5. Young RR: Spasticity: A Review. Neurology 1994; 44: S12-S20..
6. Bucy PC: Studies on the human neuromuscular mechanism. II. Effects of ventromedial chordotomy on muscular spasticity in man. Arch Neurol Psychiatry 1938; 40: 639-662.
7. Hyndman OR: Physiology of the spinal cord. II. The influence of chordotomy on existing motor disturbance. J Neurol Ment Dis 1943; 98: 343-355.
8. Jerusalem F: A double blind study on the antispastic action of beta (4-chlorophenyl) - gamma-amino butyric acid in multiple sclerosis. Nervenarzt 1968; 39: 515.
9. Levine IM, Jossmann PB, De Angelis V: Lioresal, a new muscle relaxant in the treatment of spasticity: a double blind quantitative evaluation. Dis Nerv Sys 1977; 38: 1011-1015.
10. Pedersen E, Arlien-Soborg P, Mai J: The mode of action of the BAGA derivative baclofen in human spasticity. Acta Neurol Scand 1974; 50: 665-680.
11. United Kingdom Tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994; 44 (sup.9): 70-79.
12. Nance PW, Bugaresti J, Shellenberger K et al: Efficacy and safety of tizanidine in patients with spinal cord injury. Neurology 1994; 44 (suppl.9): 445-448.
13. Stein R, Nordal HJ, Offendal SI et al: Treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spasticity drug tizanidine compared with baclofen. Acta Neurol Scand 1987; 75: 190-194.
14. Roussan M, Terrence C, Fromm G: Baclofen versus diazepam for the treatment of spasticity and long term follow-up of baclofen therapy. Pharmatherpeutica 1987; 4: 278-284.
15. Dall JT, Harmon RL, Quinn CM: Use of clonidine for treatment of spasticity arising from various forms of brain injury: large series. Brain Inj 1996; 10: 453-458.
16. Tolosa ES, Soll RW, Loeweason R: Treatment of spasticity in multiple sclerosis with dantrolene. JAMA 1975; 233 (10): 1046.
17. Katrak PH, Cole A, Poulos CJ et al: Objective assessment of spasticity, strength and function with early exhibition of dantrolene sodium after after cerebrovascular accident: a randomized double-blind study. Arch Phys Med Rehabil 1992; 73: 4-9.
18. Pribe MM, Sherwood AM, Graves DE et al: Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997; 35: 171-175.
19. Snow BJ, Tsui JKC, Bhatt MH et al: Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990; 28: 512-515.
20. Koman LA, Mooney JF, Smith BP et al: Botulinum toxin type a neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: A randomized, double-blind, placebo controlled trial. J pediatr Orthop 2000; 20: 108-115.
21. Wissel J, Heinen F, Schenkel A et al: Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: A randomized, double-blind study of 'high-dose' versus 'low-dose' treatment. Neuropediatrics 1999; 30: 120-124.
22. Penn RD, Savoy SM, Corcos D et al: Intrathecal baclofen for severe spinal spasticity. N Engl J Med 1989; 320: 1517-1521.
23. Nance PW, Schryvers OI, Schmidt BJ et al: Intrethecal baclofen therapy for adults with spinal spasticity: Therapeutic efficacy and effect on hospital admission. Can J Neurol Sci 1995; 22: 122-129.
24. On AY, Kirazli Y, Kismali B et al: Comparison of phenol block and botulinum toxin type A in the treatment of spastic foot after stroke: A randomized, double-blind tral. Am J Phys Med Rehabil 1998; 77: 510-515.
25. Nishida F, Thatcher SW, Marty GR: Selective posterior rhizotomy for children with cerebral palsy. A 7 year experience. Childs Nerv Syst 1995; 11: 374-380.